Innovative approaches in oral, inhalational, and transdermal drug delivery for cancer and diabetes treatment.

Wong Tin Wui

Oral, pulmonary, and transdermal drug delivery is challenged by the anatomical and physiological attributes of the respective route of administration. The oral drug delivery is met with harsh gastrointestinal environment which renders therapeutic degradation and reduced ease of drug targeting. The pulmonary drug delivery, specifically via nanoparticulate carriers, is susceptible to drug exhalation due to breathing process and complex lung structure disfavouring deep or peripheral lung deposition of drug. Transdermal drug delivery is hindered by stratum corneum, the outermost skin layer, thus limiting transmucosal drug diffusion even though the drug is processed in the form of nanoparticles. This presentation aims to highlight innovative approaches that have been explored for oral, pulmonary, and transdermal delivery of cancer therapeutics and anti-diabetic protein drug. The cancer therapeutics are characterized by adverse effects over the normal cell populations. The protein drug, such as insulin, is prone to biodegradation and has a relatively low bioavailability with respect to non-injection mode of administration. The consideration of the nature of therapeutics and their routes of administration is imperative to succeed drug delivery.

TRANSDERMAL medication; SKIN permeability; CANCER treatment; HYPOGLYCEMIC agents; PROTEIN drugs; DRUG administration; TARGETED drug delivery

Current Trends in Biotechnology & Pharmacy, 2020, p7

0973-8916

Academic Journal